Search

Search Results

• THE TREATMENT OF ADVANCED-STAGE MYCOSIS FUNGOIDES AND SEZARY SYNDROME: A HEMATOLOGIST'S POINT OF VIEW.

  Antonio Giordano, Livio Pagano

  e2022029

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.029

  1902

  PDF: 990

  HTML: 234

• PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis

  Fiorina Giona

  e2021069

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.069

  1728

  HTML: 1335

  PDF: 1003

• TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin

  Cristina Papayannidis, Vincenzo Federico, Luana Fianchi, Patrizia Pregno, Novella Pugliese, Alessandra Romano, Federica Irene Grifoni

  e2022073

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.073

  1144

  PDF: 905

  HTML: 186

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  1858

  PDF: 1321

  HTML: 244

• THE ROLE OF CORTICOSTEROIDS IN ADULT RESPIRATORY DISTRESS SYNDROME CAUSED BY VIRIDANS GROUP STREPTOCOCCI BACTEREMIA IN NEUTROPENIC PATIENTS

  Abraham Tareq Yacoub, Lysenia Mojica, Lily Jones, Andrea Knab, Sally Alrabaa, John Norman Greene

  e2014055

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.055

  1966

  PDF: 802

  HTML: 1835

  Table: 204

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  3663

  PDF: 3019

  HTML: 181

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4225

  PDF: 1438

  HTML: 3601

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  1818

  PDF: 813

  HTML: 1213

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1405

  PDF: 885

  HTML: 207

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2043

  PDF: 1916

  HTML: 137

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  1938

  PDF: 1442

  HTML: 255

• Ixazomib-associated skin exfoliation

  Yali Zhang, Long Zhao, Yuancheng Guo, bei liu

  e2022045

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.045

  762

  PDF: 503

  HTML: 180

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2028

  PDF: 1115

  HTML: 1964

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1315

  PDF: 579

  HTML: 216

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2558

  PDF: 3082

  HTML: 306

• Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

  Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

  e2016016

  2016-02-20

  https://doi.org/10.4084/mjhid.2016.016

  2837

  PDF: 659

  HTML: 1918

  figure 1: 144

  figure 2: 156

• Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. immune thrombocytopenia following mRNA vaccine

  SIMONA BIANCHI, ALESSIA ANGI, MAURO PASSUCCI, GIOVANNA PALUMBO, ERMINIA BALDACCI, ANNA MARIA TESTI

  e2022011

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.011

  2040

  PDF: 511

  HTML: 1123

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1588

  PDF: 1590

  HTML: 730

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3600

  PDF: 1009

  HTML: 1778

• ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

  Daniel Olson, Abraham Tareq Yacoub, Gelenis Domingo, John Norman Greene

  e2014068

  2014-08-28

  https://doi.org/10.4084/mjhid.2014.068

  1751

  PDF: 686

  HTML: 2082

  Untitled: 186

  Untitled: 137

  Untitled: 151

  Untitled: 137

  Untitled: 144

  Untitled: 160

  Untitled: 166

• Immune thrombocytopenic purpura cases following COVID-19 vaccination.

  Annalisa Condorelli, Uros Markovic, Roberta Sciortino, Mary Ann Di Giorgio, Daniela Nicolosi, Gaetano Giuffrida

  e2021047

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.047

  1057

  PDF: 383

  HTML: 295

• LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

  Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

  e2011021

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.021

  1527

  PDF: 761

  HTML: 838

  jdoe, table 2 infections CML .doc: 170

  jdoe, table 1 infections CML .doc: 158

• EBV AND HIV-RELATED LYMPHOMA

  Michele Bibas, Andrea Antinori

  e2009032

  2009-12-29

  https://doi.org/10.4084/mjhid.2009.032

  1438

  PDF: 603

  HTML: 6786

• WHAT ARE FUNGAL INFECTIONS?

  Ben E de Pauw

  e2011001

  2011-01-03

  https://doi.org/10.4084/mjhid.2011.001

  3992

  PDF: 2290

  HTML: 27528

  de Pauw: 205

• HIGHLIGHTS ON THE CONTRIBUTION OF GUT MICROBIOTA TO IMMUNE-MEDIATED DISEASES IN CHILDHOOD Gut microbiota in childhood immune-mediated diseases

  Donato Rigante, Helena Pelanda, Eleonora Rulli, Murad Sultanov, Susanna Adornato

  e2026025

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.025

  843

  PDF: 409

  HTML: 61